These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17725208)

  • 1. [Anemia and cardiovascular risk in the chronic kidney disease population--which hemoglobin target should be reached?].
    Krzesinski JM; Dubois B
    Rev Med Liege; 2007; 62(5-6):366-70. PubMed ID: 17725208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target hemoglobin level for EPO therapy in CKD.
    Parfrey PS
    Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399
    [No Abstract]   [Full Text] [Related]  

  • 3. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
    Drüeke TB; Locatelli F; Clyne N; Eckardt KU; Macdougall IC; Tsakiris D; Burger HU; Scherhag A;
    N Engl J Med; 2006 Nov; 355(20):2071-84. PubMed ID: 17108342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: con.
    Himmelfarb J; Szczech LA
    J Am Soc Nephrol; 2009 Jul; 20(7):1441-3. PubMed ID: 19579287
    [No Abstract]   [Full Text] [Related]  

  • 6. An economic evaluation of erythropoiesis-stimulating agents in CKD.
    Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
    Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results of anemia treatment with darbepoetin alfa and erythropoietin beta in patients with chronic kidney disease].
    Wanic-Kossowska M
    Pol Merkur Lekarski; 2010 Jan; 28(163):13-7. PubMed ID: 20369716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure.
    Fishbane S; Miyawaki N
    Kidney Int; 2010 Feb; 77(3):175-7. PubMed ID: 20075952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target.
    KDOQI
    Am J Kidney Dis; 2007 Sep; 50(3):471-530. PubMed ID: 17720528
    [No Abstract]   [Full Text] [Related]  

  • 10. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.
    Go AS; Yang J; Ackerson LM; Lepper K; Robbins S; Massie BM; Shlipak MG
    Circulation; 2006 Jun; 113(23):2713-23. PubMed ID: 16754803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?
    Berns JS
    Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):567-72. PubMed ID: 20601876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do we know the correct hemoglobin target for anemic patients with chronic kidney disease?
    Foley RN
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):678-84. PubMed ID: 17699272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anemia: guidelines comparison].
    Del Vecchio L
    G Ital Nefrol; 2009; 26(6):686-94. PubMed ID: 19918751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anemia as a risk factor for CKD and CVD].
    Tsuruya K; Hirakata H
    Nihon Rinsho; 2008 Sep; 66(9):1786-93. PubMed ID: 18788410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro.
    Singh AK
    J Am Soc Nephrol; 2009 Jul; 20(7):1436-41. PubMed ID: 19579295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of target hemoglobin levels during the first year of epoetin treatment in patients with chronic kidney disease.
    De Nicola L; Conte G; Chiodini P; Cianciaruso B; Pota A; Bellizzi V; Tirino G; Avino D; Catapano F; Minutolo R
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):938-46. PubMed ID: 17724278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hemoglobin targets in anemic patients with chronic kidney disease treated with erythropoietin].
    Baglin A; Hanslik T; Prinseau J; Moulonguet-Doleris L
    Rev Med Interne; 2008 Oct; 29(10):846-51. PubMed ID: 18054410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anemia and cardiovascular risk: the lesson of the CREATE Trial.
    Locatelli F; Del Vecchio L; Pozzoni P
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S262-6. PubMed ID: 17130272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.